Table 8. Maternal secondary outcomes*.
| Outcome | Studies contributing data | MgSO4 | Control | RR | LCL | UCL | p† |
|---|---|---|---|---|---|---|---|
| Dichotomous | |||||||
| Adverse event leading to stopping treatment | 9,10,11,12,13 | 115/2,310 (5.0%) | 58/2,337 (2.5%) | 1.95 | 1.44 | 2.65 | 0.11 |
| Intrapartum fever treated with antibiotics | 9,11 | 237/603 (39.3%) | 227/592 (38.3%) | 1.05 | 0.94 | 1.18 | 0.37 |
| Clinical chorioamnionitis during labour | 9,11,13 | 323/1,695 (19.1%) | 326/1,738 (18.8%) | 1.00 | 0.87 | 1.14 | 0.92 |
| Caesarean delivery | 9,10,11,12,13 | 1,310/2,727 (48.0%) | 1,282/2,766 (46.3%) | 1.04 | 0.98 | 1.10 | 0.38 |
| Postpartum haemorrhage | 9,10,11,12 | 410/1,457 (28.1%) | 410/1,458 (28.1%) | 1.01 | 0.90 | 1.13 | 0.99 |
Abbreviations: LCL, lower confidence limit; UCL, upper confidence limit. The trials included are as follows: 9 = Australasian Collaborative Trial of Magnesium Sulphate (ACTOMgSO4), 10 = PREterm brain protection by MAGnesium sulphate (PREMAG), 11 = Magnesium and Neurologic Endpoints Trial (MAGNET), 12 = MAGnesium sulphate for Prevention of Eclampsia (MAGPIE), and 13 = Beneficial Effects of Antenatal Magnesium Sulfate (BEAM).
*Overall results from 1-stage individual participant data (IPD).
†p-values for heterogeneity (the heterogeneity p-value for 1-stage analyses is from Wald chi-square tests for the interaction between treatment and trial in a generalising estimating equation [GEE] model).